Agilent Technologies Inc. (A) — RQD Stock Rating Cockpit

Per the Roarable RQD rating, Agilent Technologies scores 75 out of 100, a letter grade of B, labeled "Roarable Buy — Good Risk/Reward." The five pillars break down as follows:

• Fundamental Cash Engine: 15 / 20. Per the RQD rating, this pillar reflects ROIC of 15.3% and an FCF yield of 2.26%. For an investor, the return on invested capital is solid, but the 2.26% free-cash-flow yield at the current price implies that the market is paying a premium for each dollar of cash generated, which is a valuation tradeoff rather than a discount.
• Whale 13F Flow: 18 / 20. The RQD rating describes this pillar as reflecting institutional accumulation and options positioning. This is the strongest pillar in the composite, suggesting that large institutional holders have been adding exposure. The underlying 13F holder records are not provided in the source data, so the magnitude of accumulation cannot be verified here.
• Insider Conviction: 12 / 20. Per the RQD rating, this reflects SEC Form 4 and Congressional PTR cluster flow. A moderate score indicates insider and political-disclosure activity that is supportive but not decisively bullish. Individual transaction detail is not available in the source data.
• Macro Regime Fit: 12 / 20. Per the RQD rating, this pillar reflects a beta of 0.91 and sector sensitivity. A beta below 1.0 means the stock has historically moved less than the broad market, which can cushion drawdowns but also limits participation in strong market rallies. The score is middling, indicating neither a strong tailwind nor a clear headwind from the macro regime.
• Forensic Balance Sheet: 18 / 20. Per the RQD rating, this pillar reflects an Altman Z-Score of 6.5, a Piotroski F-Score of 9/9, and Debt/Equity of 0.36. These are strong readings that point to low near-term financial distress risk and high reported financial quality.

Taken together, the composite suggests a company with a financially strong balance sheet and institutional support, offset by a premium valuation (trailing P/E of 39.2) and only moderate macro-regime alignment. The upside drivers are balance-sheet resilience and institutional interest; the valuation tradeoff is that the price already reflects much of the expected quality.

Agilent Technologies Inc. is listed on the NYSE and classified under the Health Care sector. Per the company profile, it operates in the Biotechnology: Laboratory Analytical Instruments industry. The source data does not provide detail on specific products, customer segments, or revenue mix. Per the SEC financials, the company generated revenue of $6948.0M in FY 2025.

Per the market data, gross margin is 52.4%, operating margin 21.3%, and net margin 18.8%, with ROIC of 15.3%. Per the Roarable RQD rating, the Altman Z-Score is 6.5 and the Piotroski F-Score is 9/9, both pointing to strong financial health. Debt/Equity is 0.36 per the RQD rating. Reported debt was $2657.2M in FY 2025 against cash of $1758.0M, and FY 2023 debt is reported at $6572.9M with cash not available in source data. Revenue moved from $6833.0M (FY 2023) to $6510.0M (FY 2024) and back to $6948.0M (FY 2025), while operating income and net income stayed in a narrow band.

The news wire contains six items, all tagged to A. Headlines describe market action and outperformance (Yahoo Finance, MarketWatch), a Trefis note on management raising expectations, a Benzinga long-horizon return piece, a Yahoo Finance item on the opening of an energy materials research center, and a Simply Wall St forecast piece. Items are flagged GREEN (catalyst) or YELLOW (market wire). The source data does not include the body text of these articles, so the substance of the catalysts cannot be independently verified. The Butterfly Supply-Chain Graph reports no proprietary signals and no supply-chain links.

Per the Butterfly Supply-Chain Graph, the supply chain is recorded as NONE, with no butterfly links and no proprietary signals. Upstream suppliers, downstream customers, and sector correlations are not available in source data. An investor should note that the absence of mapped links means this brief cannot assess second-order ripple effects from supplier or customer disruptions.

• What are the specific products and end-markets driving the FY 2025 revenue of $6948.0M, and how is revenue mix distributed?
• Why is FY 2025 EPS and FY 2024 EPS reported as N/A, and what is the reported diluted share count?
• What explains the swing in reported debt between FY 2023 ($6572.9M) and FY 2024–2025 (roughly $2.6B), and what is FY 2023 cash?
• What do the institutional 13F filings and Form 4 insider transactions specifically show, given that the holders section is empty?
• Do analyst consensus ratings and price targets exist, given that the analyst data section is empty?